Project Grant R01CA290813
Award Date
9/1/24
Completion Date
8/31/29
Dollars Obligated
$518K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Aurora, CO 80045, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports a research project at the University of Miami aimed at improving the survival rate of patients with metastatic, endocrine-resistant breast cancer. The $447,340 award, effective March 1, 2025 through February 28, 2030, will fund research to identify epigenetic vulnerabilities and therapeutic targets in breast cancer cells that have developed resistance to endocrine therapy. Specifically,...
This $895,779 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to advance the science of brain metastases from HER2-positive breast cancer. The key products and services to be delivered under this 7-year grant include: Understanding the fundamental biology and genetic risk factors of HER2-positive breast cancer metastases to the brain through patient tissue-based research. Developing real-time visualization techniques to track cancer cells and...
The National Cancer Institute (NCI) awarded Emory University a $1,291,898 Project Grant under the Cancer Treatment Research federal grant program (CFDA 93.395) to conduct research aimed at enhancing the effectiveness of radiation therapy and immune checkpoint inhibitor (ICI) treatments for breast cancer. The key objectives are to: 1) determine how the protein SAMHD1 directs radiation and immunological dynamics that influence response to ICI, 2) investigate the role of SAMHD1 in directing...
The federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $647,118 to the University of Colorado-Denver to study the role of the EYA3/PP2A pathway in regulating triple negative breast cancer (TNBC) metastasis. The research aims to determine the molecular and cellular mechanisms by which the EYA3-NF-κB axis enhances TNBC metastasis, and to understand how EYA3 regulates NF-κB signaling through its interaction with the PP2A-B55α subunit. The...
The National Cancer Institute (NCI) awarded a $2,104,477 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to study resistance mechanisms and enhance response to immune checkpoint blockade in central nervous system (CNS) metastases from breast cancer. The project aims to characterize the co-evolution of cancer and the immune system during immunotherapy in CNS metastases by profiling...
This $204,295 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to the University of Alabama at Birmingham aims to leverage advanced PET/MRI imaging to quantify HER2 expression and vascularity in HER2+ breast-to-brain metastases. The overarching goal is to use these imaging biomarkers to noninvasively assess intratumoral heterogeneity and delivery of systemic targeted therapies, in order to predict treatment response to combination...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,200,000 to Creative Biotherapeutics LLC, a biotechnology research firm, to develop a novel biologic therapy to eradicate brain cancer and brain metastases. The project aims to target the extracellular glucose-regulated protein 78 (eGRP78), which is upregulated in drug-resistant recurrent brain cancers and promotes tumor growth, immune evasion, and stem cell formation. The...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program provides $161,000.00 to Duke University to conduct research on "Breast Cancer Brain Metastases: Integrating Immunogenomic and Phenotypic Vulnerabilities to Improve Outcomes." The research aims to explore innovative approaches to the prevention, diagnosis, and treatment of breast cancer brain metastases, with a focus on integrating immunogenomic and...
This $2,131,064 federal Project Grant awarded by the Department of Defense's Military Medical Research and Development program (CFDA 12.420) to the University of Colorado-Denver supports research on the effects of androgen receptors in luminal breast cancer. The four-year project, titled "ANDROGEN RECEPTORS IN LUMINAL BREAST CANCER: EFFECTS ON RESPONSE TO ENDOCRINE THERAPY AND AN IMMUNE-SUPPRESSIVE TUMOR IMMUNE MICROENVIRONMENT (TIME)", aims to investigate how androgen receptor...
This Project Grant award of $700,690 from the National Cancer Institute's (NCI) Cancer Biology Research (CFDA 93.396) program supports research to decipher the molecular mechanisms of breast cancer bone metastasis. The primary awardee, Health Research, Inc. (Roswell Park Division), will conduct studies to understand how the transcriptional coactivators YAP/TAZ drive the progression of microscopic to established bone metastases in breast cancer. The research aims to determine the mechanisms of...